| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Allogeneic transplantation for patients with Philadelphia chromosome positive acute lymphoblastic leukemia: Is it imperative in the tyrosine kinase inhibitor era?
|
Litzow, Mark R.
|
|
2018
|
31 |
4 |
p. 357-360
|
article
|
| 2 |
Can haploidentical transplantation meet all patients' needs?
|
Weisdorf, Daniel
|
|
2018
|
31 |
4 |
p. 410-413
|
article
|
| 3 |
Can one target T-cell ALL?
|
Ferrando, Adolfo
|
|
2018
|
31 |
4 |
p. 361-366
|
article
|
| 4 |
Editorial Board / Aims & Scope
|
|
|
2018
|
31 |
4 |
p. iii
|
article
|
| 5 |
Hematopoietic cell transplantation as treatment of patients with acute myeloid leukemia with measurable residual disease after consolidation therapy
|
Appelbaum, Frederick R.
|
|
2018
|
31 |
4 |
p. 405-409
|
article
|
| 6 |
Identifying patients with genetic predisposition to acute myeloid leukemia
|
Obrochta, Ellyn
|
|
2018
|
31 |
4 |
p. 373-378
|
article
|
| 7 |
Is it time to routinely incorporate MRD into practice?
|
Ravandi, Farhad
|
|
2018
|
31 |
4 |
p. 396-400
|
article
|
| 8 |
Is the overall survival for older adults with AML finally improving?
|
Lancet, Jeffrey E.
|
|
2018
|
31 |
4 |
p. 387-390
|
article
|
| 9 |
Is there a standard of care for relapsed AML?
|
Medeiros, Bruno C.
|
|
2018
|
31 |
4 |
p. 384-386
|
article
|
| 10 |
Patterns of mutations in TP53 mutated AML
|
Welch, John S.
|
|
2018
|
31 |
4 |
p. 379-383
|
article
|
| 11 |
Progress and predictions: AML in 2018
|
Rowe, Jacob M.
|
|
2018
|
31 |
4 |
p. 337-340
|
article
|
| 12 |
Should immunologic strategies be incorporated into frontline ALL therapy?
|
Rank, Cecilie Utke
|
|
2018
|
31 |
4 |
p. 367-372
|
article
|
| 13 |
The role of hypomethylating agents prior to hematopoietic cell transplantation in myelodysplastic syndromes
|
Sekeres, Mikkael A.
|
|
2018
|
31 |
4 |
p. 346-350
|
article
|
| 14 |
What biologic factors predict for transformation to AML?
|
Bejar, Rafael
|
|
2018
|
31 |
4 |
p. 341-345
|
article
|
| 15 |
What FLT3 inhibitor holds the greatest promise?
|
Stone, Richard M.
|
|
2018
|
31 |
4 |
p. 401-404
|
article
|
| 16 |
Which novel agents for acute myeloid leukemia are likely to change practice?
|
Pollyea, Daniel A.
|
|
2018
|
31 |
4 |
p. 391-395
|
article
|
| 17 |
Why and how to treat Ph-like ALL?
|
Roberts, Kathryn G.
|
|
2018
|
31 |
4 |
p. 351-356
|
article
|
| 18 |
Why is a 3-year NRM following allogeneic transplantation still stuck at approximately 20%?
|
Barrett, John
|
|
2018
|
31 |
4 |
p. 414-419
|
article
|
Journal description